Medicilon’s Formulation CDMO Platform Advances Taiji Group’s Next-Generation RNA Polymerase Inhibitor DSC158A Tablets to Clinical Stage
Chongqing Fuling Pharmaceutical Factory Co., Ltd., a wholly-owned subsidiary of Chongqing Taiji Industry (Group) Co., Ltd., has received the Clinical Trial Approval Notice for DSC158A Tablets from the National Medical Products Administration (NMPA). A next-generation RNA polymerase inhibitor, DSC158A Tablets are developed for the treatment of influenza A and influenza B in adult patients. As […]
TPD CN-US Dual Filing Milestone: Medicilon’s One-Stop Platform Helps Gluetacs Secure Dual Approval for GT818, a First-in-Class RSK Degrader
August 31, 2026 —Gluetacs Therapeutics announced that GT818 capsules, its self-developed first-in-class innovative drug, has been approved by the U.S. Food and Drug Administration (FDA) to enter clinical trials for the treatment of advanced malignant tumors. The candidate previously received an implied clinical trial approval from China’s National Medical Products Administration (NMPA) on July 1, […]
World’s First Long-Acting Anti-RSV Monoclonal Antibody Xinduotuo Wins NMPA Approval — Medicilon Empower Trinomab’s Source Innovation
September 3, 2026 — The world’s first fully human long-acting anti-RSV monoclonal antibody, Xinduotuo (generic name: retavibart injection; development code: TNM001), independently developed by Zhuhai Trinomab Pharmaceutical Co., Ltd. (STAR Market: 688806, “Trinomab”), has received marketing approval from China’s National Medical Products Administration (NMPA). It is indicated for the prevention of RSV-associated lower respiratory tract […]
Novel Analgesic Breakthrough: Xinhua Pharmaceutical’s Class 1 Drug LXH-2103 Secures Clinical Approval with Medicilon’s Preclinical Support
Shandong Xinhua Pharmaceutical Co., Ltd., the core subsidiary of Shandong Hualu Holdings Co., Ltd., has obtained official clinical trial approval from the National Medical Products Administration (NMPA) for LXH-2103 Injection, its self-developed Class 1 innovative drug. The candidate is approved for clinical research in the treatment of moderate to severe postoperative pain, marking a key […]
Medicilon Empowers IxCell’s IxCell PB-ZRAK Injection to Secure Clinical Trial Approval for Advanced Hepatocellular Carcinoma
Recently, IxCell has obtained implied approval from the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for the clinical trial application of its independently developed IxCell PB-ZRAK Injection. The novel cell therapy product is indicated for the treatment of unresectable or metastatic advanced hepatocellular carcinoma (HCC) in patients with disease progression […]
EFMC-ISMC 2026
Basel, Switzerland from September 6-10, 2026
Medicilon Delivers One Stop Preclinical Support as Yizhong Pharma Secures NMPA Clinical Approval for YXC‑001 Tri‑functional Antibody Fusion Protein and YXC‑002 4th‑Generation EGFR Kinase Inhibitor
Yizhong Pharma, a STAR-Market-listed biotech company, has obtained Clinical Trial Approval Notices from the National Medical Products Administration (NMPA) for two proprietary innovative drug candidates: YXC-001, a tri functional antibody fusion protein, and YXC-002, a 4th-generation EGFR kinase inhibitor. As Yizhong Pharma’s CRO partner, Medicilon executed full-scope preclinical studies (PD, PK, Tox) for YXC -001 […]
4th SMC and AimedBio ADC Conference
Date: August 27-28, 2026
Venue:The Westin Seoul Parnas, South Korea – Medicilon Booth #6
ACS Fall 2026
Date: August 23-27, 2026
Venue: McCormick Place Convention Center, Chicago, IL – Medicilon Booth #400
【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026
Date: September 10, 2026 (Thursday)
Venue: EL Tower, Ruby Hall, Yangjae, Seoul
